InflaRx’s (IFRX) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed their buy rating on shares of InflaRx (NASDAQ:IFRX) in a report issued on Tuesday,Benzinga reports. They currently have a $14.00 price objective on the stock.

A number of other research firms have also recently issued reports on IFRX. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research report on Friday, March 27th. Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of InflaRx in a research report on Tuesday, December 30th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, InflaRx presently has an average rating of “Moderate Buy” and an average price target of $6.17.

InflaRx Trading Up 4.2%

IFRX stock opened at $1.73 on Tuesday. The firm’s 50-day moving average price is $0.98 and its two-hundred day moving average price is $1.09. InflaRx has a 12-month low of $0.71 and a 12-month high of $1.94. The stock has a market capitalization of $125.06 million, a price-to-earnings ratio of -2.28 and a beta of 1.49.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Friday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). The firm had revenue of ($0.04) million during the quarter, compared to analysts’ expectations of $0.03 million. Equities analysts predict that InflaRx will post -0.6 EPS for the current year.

Hedge Funds Weigh In On InflaRx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC increased its position in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after buying an additional 7,616 shares during the period. HRT Financial LP purchased a new position in shares of InflaRx during the fourth quarter valued at about $47,000. Concurrent Investment Advisors LLC increased its position in shares of InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after buying an additional 19,200 shares during the period. Insigneo Advisory Services LLC purchased a new position in shares of InflaRx during the fourth quarter valued at about $61,000. Finally, Quadrature Capital Ltd purchased a new position in shares of InflaRx during the fourth quarter valued at about $104,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.